D3 Bio Enhances Leadership With Dr. Antoine Yver As New Board Member

D3 Bio, a pioneering biotechnology firm with a focus on the discovery, development, and registration of innovative cancer treatments, has announced the appointment of Dr. Antoine Yver as a new independent board member, effective from March 4, 2024. Dr. Yver brings to the table an impressive 34-year tenure in the global pharmaceutical industry, particularly in the area of oncology drug discovery and development. His previous roles include Executive Vice-President and Global Head of R&D Oncology at Daiichi Sankyo and Senior Vice-President, GMed Head Oncology and GMD China lead at AstraZeneca.

Under Dr. Yver's leadership, several breakthrough medicines such as osimertinib, olaparib, and fam-trastuzumab deruxtecan were successfully developed and approved. His extensive experience and strategic vision are expected to significantly contribute to D3 Bio's mission to advance cancer treatment breakthroughs and transform patient care worldwide. "I am deeply honored to join D3 Bio and humbled by the opportunity to substantially contribute to making the world better by delivering your important science for the advancement of care of patients with cancer around the world," said Dr. Yver.

Dr. Yver's academic credentials include an MD With Honors from Paris Saclay University in 1983 and a Master of Sciences in Immunology with Honors from Paris VI, France in 1988. He also became a French board-certified Pediatrician in 1987. Currently, Dr. Yver serves as Chairman of Development at Centessa Pharmaceuticals and as an independent director on the board of Sanofi SA. Additionally, he is the Founder of 'The Blue Bears Special Meals', a non-profit dedicated to providing meaningful employment for individuals with intellectual and developmental disabilities.

Dr. George Chen, Chairman and CEO at D3 Bio, expressed his enthusiasm about Dr. Yver joining the board: "I had the privilege of working with Dr. Yver at AstraZeneca, and today I am honored to extend a warm welcome to him as our new independent board member. Dr. Yver has been a special advisor to D3 Bio since March 2023, providing strategic and scientific advice that has significantly contributed to our company. In his new role, I am confident that Dr. Yver will play a pivotal role in steering D3 Bio towards becoming an established global biotech company."

About D3 Bio: D3 Bio is a clinical-stage biotechnology company globally oriented towards oncology and immunology. Leveraging clinical insight and biomarker strategies, D3 Bio aims to develop novel therapies that offer significant clinical benefits to patients in need. The company is supported by globally renowned investors including Boyu Capital, Matrix Partners China, Sequoia Capital China, Temasek, and WuXi AppTec's Corporate Venture Fund.

For media inquiries, please contact Rui Liu, Head of Corporate Affairs at [email protected] or Bob Aibai at gobyglobal.com.